Dysphagia in Eosinophilic Esophagitis: Practical Management Strategies

Dysphagia remains one of the most common and distressing symptoms reported by patients with eosinophilic esophagitis (EoE). Across Australia, gastroenterologists and allergists are seeing increasing numbers of adults and children present with food bolus impaction, intermittent swallowing difficulties, and a long history of compensatory behaviours such as prolonged chewing and fluid chasers during meals.

The therapeutic landscape has shifted considerably over the past decade, moving beyond simple acid suppression to targeted anti-inflammatory agents and structured elimination diets. Specialists attending recent congress sessions discussed how these evolving options can be tailored to individual phenotypes, particularly given the unique realities of the Australian healthcare environment where both metropolitan tertiary centres and remote outreach services shape the patient journey.

Recognising EoE in Patients with Dysphagia

Eosinophilic esophagitis is a chronic, immune-mediated condition characterised by eosinophilic infiltration of the oesophageal mucosa. In adults, dysphagia is often the predominant symptom, with food becoming transiently stuck and requiring urgent endoscopic intervention in up to a third of cases. Children, by contrast, may present with feeding difficulties, vomiting, or failure to thrive, which complicates early recognition in general practice.

The diagnostic threshold requires a minimum of 15 eosinophils per high-power field on biopsy, typically obtained from multiple oesophageal sites. Australian clinicians increasingly rely on the Endoscopic Reference Score (EREFS) to standardise reporting, which has improved communication between endoscopists in Brisbane, Sydney, and Perth where pathology services are concentrated.

Navigating Diagnostic and Therapeutic Decisions Locally

Australian management is shaped by Medicare reimbursement schedules, which dictate the frequency of gastroscopies and the availability of histology reviews. Most patients first encounter the public hospital system in major cities such as Melbourne or Adelaide, where waiting lists for elective endoscopy can extend beyond three months for non-urgent cases. This delay often prompts private referrals, and out-of-pocket costs influence whether patients proceed promptly with biopsies or defer investigation. For clinicians weighing differential diagnoses, obesity-related GERD patterns sometimes overlap with EoE symptoms, and a careful history can clarify the clinical picture.

Allergy testing forms an important adjunct, given the strong association between EoE and atopic conditions such as asthma, allergic rhinitis, and eczema. Skin prick testing and serum-specific IgE panels are widely available through specialist immunology clinics, though rural and remote patients in regions like the Northern Territory often rely on telehealth consultations to access these services.

Dietary and Pharmacological Treatment Strategies

The three-food elimination diet (TFED) and the more comprehensive six-food elimination diet (SFED) remain cornerstone therapies in Australia, particularly for motivated patients willing to undergo serial endoscopies. Practical adaptation often involves working with local dietitians to navigate the Australian food supply, where wheat-based products, dairy alternatives such as soy or oat milk, and native ingredients require careful substitution.

Pharmacologically, proton pump inhibitors (PPIs) continue to be used both diagnostically and therapeutically, with a subset of patients showing histological remission. Topical corticosteroids, including swallowed fluticasone and budesonide preparations, are increasingly funded through the Pharmaceutical Benefits Scheme (PBS) for refractory disease. Dupilumab, the monoclonal antibody targeting IL-4 and IL-13, has recently received Therapeutic Goods Administration (TGA) approval and is reshaping treatment for steroid-refractory cases across the country.

Endoscopic Dilatation and Procedural Considerations

When strictures or fibrostenotic changes cause persistent dysphagia, endoscopic dilatation offers meaningful symptomatic relief. Bougies and through-the-scope balloon dilators are both used across Australian endoscopy units, with choice often dictated by operator preference and lesion morphology. The risk of perforation and post-procedural chest pain is discussed openly with patients, and informed consent typically includes a brief description of recovery expectations.

In centres equipped with EndoFlip technology, real-time assessment of oesophageal distensibility is gaining traction, particularly for evaluating treatment response beyond histology. Tertiary hospitals in Sydney and Melbourne have published outcomes data supporting the use of these functional measurements to guide escalation of therapy.

Building a Multidisciplinary Pathway for Long-Term Care

Sustained management of EoE requires collaboration between gastroenterologists, allergists, dietitians, speech pathologists, and often psychologists, given the anxiety and social disruption that chronic dysphagia can produce. Australian public hospitals are increasingly embedding nurse-led EoE clinics to coordinate care, streamline endoscopies, and reinforce dietary adherence between specialist visits.

Telehealth has become a vital adjunct, particularly for patients in the Wheatbelt of Western Australia, the Riverina in New South Wales, or coastal communities in Queensland where specialist access is limited. Regular virtual reviews allow dose adjustments of topical steroids, monitoring of growth parameters in paediatric patients, and timely escalation when symptoms recur after periods of remission.

The principal message for clinicians is that successful management of dysphagia in eosinophilic esophagitis depends on early recognition, accurate histological confirmation, and a flexible combination of dietary, pharmacological, and endoscopic interventions tailored to the individual. Australian patients benefit most when their care team embraces shared decision-making, recognises the practical realities of geography and healthcare funding, and remains alert to evolving therapies that continue to redefine what remission looks like in this complex disease.